PetVivo Holdings (PetVivo Holdings) 3-Year EPS without NRI Growth Rate : -30.30% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PetVivo Holdings 3-Year EPS without NRI Growth Rate?

PetVivo Holdings's EPS without NRI for the three months ended in Dec. 2023 was $0.00.

During the past 3 years, the average EPS without NRI Growth Rate was -30.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of PetVivo Holdings was 63.20% per year. The lowest was -30.30% per year. And the median was 17.35% per year.

Competitive Comparison of PetVivo Holdings's 3-Year EPS without NRI Growth Rate

For the Medical Devices subindustry, PetVivo Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PetVivo Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where PetVivo Holdings's 3-Year EPS without NRI Growth Rate falls into.

PetVivo Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

PetVivo Holdings (OTCPK:PETVW) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

PetVivo Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

PetVivo Holdings (PetVivo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETVW) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

PETV:USA

Address

5251 Edina Industrial Boulevard, Edina, MN, USA, 55439

Website

https://www.petvivo.com

PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.